Tapentadol: Clinical Trials

23 trials of Tapentadol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 5 terminated. 23 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 323Completed 18, Terminated 5
Phase 21Completed 1

Follow Tapentadol: new trials by email Literature Review of Tapentadol trials Research Report on Tapentadol

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty.Tapentadol vs Oxycodone vs Placebo
Tapentadol, Oxycodone, Placebo - Joint Diseases
Phase 3CompletedSt. Olavs Hospital1342015-09-012021-11-16
A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain
Tapentadol prolonged release, Morphine prolonged release - Pain
Phase 2 / Phase 3CompletedGrünenthal GmbH732015-04-292019-09-12
A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain
Tapentadol oral solution 4 mg/mL, Tapentadol oral solution 20 mg/mL, Placebo - Acute Pain
Phase 3CompletedGrünenthal GmbH2162015-02-192020-01-18
Tapentadol in Chronic Malignant Tumour Related Pain
Tapentadol Prolonged Release - Cancer, Chronic Pain
Phase 3TerminatedGrünenthal GmbH312011-03-012019-11-04
A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain
Oxycodone CR, R331333 (referred to as JNS024 ER or CG5503) - Pain
Phase 3CompletedJanssen Research & Development, LLC3432010-08-012017-07-21
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability
Tapentadol Prolonged Release - Pain, Chronic Pain
Phase 3TerminatedGrünenthal GmbH1362009-10-302019-01-09
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
Tapentadol PR, Observation period - Chronic Pain, Low Back Pain
Phase 3CompletedGrünenthal GmbH2082009-09-302019-01-15
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic
Tapentadol - Chronic Pain, Osteoarthritis
Phase 3CompletedGrünenthal GmbH2242009-09-012019-10-21
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.
Tapentadol PR - Chronic Pain, Osteoarthritis
Phase 3TerminatedGrünenthal GmbH822009-09-012019-10-18
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain
NUCYNTA, Oxycodone IR - Pain, Back Pain
Phase 3CompletedOrtho-McNeil Janssen Scientific Affairs, LLC6672009-09-012012-12-19
A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
oxycodone CR, oxycodone IR, Tapentadol ER (CG5503) - Joint Diseases, Arthritis
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.5972008-10-012012-02-13
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.
Tapentadol (CG5503), oxycodone, placebo - Arthralgia, Bunion
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.9012008-02-012014-05-09
Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain
tapentadol (CG5503) Immediate Release IR, tapentadol (CG5503) Extended Release (ER), tapentadol (CG5503) Immediate Release (IR) - Low Back Pain
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.1172007-12-012015-04-15
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
Tapentadol Extended Release, Matching Placebo after Tapentadol in the Titration Phase., Morphine Sulphate Controlled Release - Tumor, Pain
Phase 3CompletedGrünenthal GmbH6222007-07-012019-11-04
A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine
Tapentadol in the Titration Phase, Morphine in the Maintenance Phase, Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase - Pain, Neoplasm
Phase 3TerminatedGrünenthal GmbH1362007-06-012019-11-01
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
Tapentadol (CG5503) Extended Release (ER) - Pain, Osteoarthritis
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.11662007-06-012014-05-09
A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy
Morphine, CG5503 IR, Placebo - Hysterectomy, Postoperative
Phase 3CompletedGrünenthal GmbH8542007-05-012019-10-28
A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy
CG5503, placebo - Diabetic Neuropathy
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.3952007-04-012013-07-19
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain
tapentadol (CG5503) ER, oxycodone CR, placebo - Low Back Pain
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.9812007-02-012012-04-30
Tapentadol (CG5503)
oxycodone, placebo, tapentadol (CG5503) - Osteoarthritis, Knee, Pain
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.10302007-01-012012-04-18

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Pain (15)  ·  Chronic Pain (8)  ·  Low Back Pain (7)  ·  Osteoarthritis (6)  ·  Arthralgia (4)  ·  Agnosia (3)  ·  Neoplasms (3)  ·  Acute Pain (2)  ·  Back Pain (2)  ·  Joint Diseases (2)  ·  Osteoarthritis, Knee (2)  ·  Abdomen, Acute (1)  ·  Arthritis (1)  ·  Bunion (1)  ·  Cancer Pain (1)

Sponsors

Grünenthal GmbH (10)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (10)  ·  Janssen Research & Development, LLC (1)  ·  Ortho-McNeil Janssen Scientific Affairs, LLC (1)  ·  St. Olavs Hospital (1)

Countries

Poland (8)  ·  Spain (8)  ·  France (7)  ·  Germany (7)  ·  United States (7)  ·  United Kingdom (6)  ·  Hungary (5)  ·  Bulgaria (4)  ·  Belgium (3)  ·  Canada (3)  ·  Croatia (3)  ·  Czechia (3)  ·  Italy (3)  ·  Romania (3)  ·  Russia (3)

Top investigators

Barbara Hoggart, Dr. MD (1)  ·  Hans Georg Kress, Dr. (1)  ·  Hans Kress, Prof. MD (1)  ·  Hans-Georg Kress, Prof. Dr. med (1)  ·  Jaime Calvo, Dr. MD (1)  ·  P. Poulain, Dr. (1)  ·  Petter Aadahl, md phd (1)  ·  Tomasz Rechberger, Prof. (1)

Results publications

PMID 23340531, PMID 24985410, PMID 23709304, PMID 24353047, PMID 24916058, PMID 19445652, PMID 20119464, PMID 20602712, PMID 21162697, PMID 21494892, PMID 22443293, PMID 22792000, PMID 23475406, PMID 23703422, PMID 23937387, PMID 25054392, PMID 26428249, PMID 27062079, PMID 32773594, PMID 35482392

NIH funding

2009 (5), 2015 (1)